Federal Court Blocks Mifepristone by Mail in All 50 States

A federal appeals court on Friday blocked mifepristone from being prescribed by telehealth and mailed to patients anywhere in the United States, a nationwide ruling that immediately cut off access for millions of women in states where abortion is fully legal.

The Fifth Circuit Court of Appeals, ruling unanimously, reversed an FDA rule from 2023 that had allowed the abortion pill to be dispensed by certified mail-order and retail pharmacies after a remote prescription. The injunction took effect immediately.

The drug itself isn’t banned. But every patient who wants it must now visit a clinic or physician’s office in person, a requirement the FDA had lifted after years of safety data showed the medication was safe to prescribe remotely. Drugmakers filed emergency appeals to the Supreme Court the following day.

What the Court Decided

The lawsuit was brought by Louisiana and other states arguing the FDA had exceeded its authority when it relaxed the in-person dispensing requirement. The Fifth Circuit agreed, at least temporarily, and blocked the 2023 rule while the underlying case continues.

Because the FDA operates nationally, the injunction applies in every state — including California, New York, Massachusetts, and others where abortion remains unrestricted.

Judge Stuart Kyle Duncan, writing for the panel, framed the decision pointedly. “By ending the in-person dispensing requirement, FDA opened the door for mifepristone to be remotely prescribed to Louisiana women,” he wrote.

Louisiana Attorney General Liz Murrill, who filed the underlying lawsuit, called the ruling a victory against what she described as the “Biden abortion cartel” that had “facilitated the deaths of thousands of Louisiana babies through illegal mail-order abortion pills.”

What It Means for Patients

The scope is significant. More than 60 percent of all U.S. abortions now use the medication regimen. Through the first six months of 2025, more than 27 percent of all abortions in the country were provided via telehealth appointments, up from fewer than 10 percent in 2022. The ruling lands in the same broader fight over reproductive-health access that has reshaped clinic operations in recent months — including Planned Parenthood’s largest U.S. affiliate launching $9 Botox cosmetic services in California after Medicaid cuts forced five of its clinics to close.

Both of those access pathways are now blocked pending a Supreme Court decision.

Patients in states where abortion is legal who had been filling mifepristone prescriptions through telehealth services or at a CVS or Walgreens must now find a clinic and visit in person. Rural patients who relied on mail access because no clinic was within reach are among those most directly affected.

California Gov. Gavin Newsom said access had been “particularly critical for women in rural and underserved communities” and that California would “continue to stand for a woman’s right to choose.”

One option remains open: misoprostol, the second drug in the standard two-drug regimen, is not subject to the same federal dispensing rules and can still be obtained without an in-person visit. The misoprostol-only regimen is less effective than the combination approach but remains legal everywhere.

Drugmakers Rush to the Supreme Court

Danco Laboratories, which makes the brand-name version Mifeprex, filed an emergency application with the Supreme Court on Saturday, asking the justices to pause the Fifth Circuit’s order while litigation continues. Generic manufacturer GenBioPro filed a separate application the same day.

Both were directed to Justice Samuel Alito, who oversees the Fifth Circuit as its assigned circuit justice.

Danco’s filing said the ruling “injects immediate confusion and upheaval into highly time-sensitive medical decisions — and it forces Danco, FDA, certified Mifeprex providers, patients, and pharmacies all to guess at what is allowed and what is not.”

As of Sunday morning, the Supreme Court had not publicly responded to either application. The injunction remains in effect while the Court weighs the requests.

Updated May 4, 2026: Justice Samuel Alito issued an administrative stay Monday on both Danco’s and GenBioPro’s applications, temporarily blocking the Fifth Circuit’s order and restoring telehealth and mail access to mifepristone until 5 p.m. on May 11. Alito also directed the parties in the underlying Louisiana v. FDA litigation to file briefs by 5 p.m. Thursday, May 7. The administrative stay does not resolve the merits; it only freezes the lower-court order while the full Court considers whether to issue a longer stay. See the Sources block for coverage of Monday’s order.

Nancy Northup, president of the Center for Reproductive Rights, called the ruling “a political blockade.” She said telehealth had become “the last bridge to care for many seeking abortion, which is precisely why Louisiana officials want it banned.”

What Comes Next

The underlying case, Louisiana v. FDA, continues in the Fifth Circuit. A full merits ruling could take months. If the Supreme Court declines to pause Friday’s order, the in-person requirement stays in place throughout.

The case could ultimately reach the Supreme Court for a full merits review. In 2024, the Court dismissed an earlier challenge to the FDA’s approval of mifepristone entirely, ruling that the plaintiffs — anti-abortion medical groups — lacked standing to sue. This time the plaintiffs are states, and their standing is not in dispute.